Drug Discovery World

OCTOBER 27, 2023

HB-400, a novel arenaviral therapeutic vaccine developed by HOOKIPA Pharma and Gilead Sciences, has been shown to generate robust T cell responses specific to hepatitis B virus with high antibody levels in a preclinical setting. A Phase I clinical trial to evaluate the safety and tolerability of HB‑400 in humans is ongoing.

Vaccine 130

Vaccine Immune Response Virus Clinical Trials 130

Drug Discovery World

MARCH 27, 2023

The first subjects have been dosed in a Phase I clinical trial of VXX-401, an investigational vaccine designed to lower low-density lipoprotein (LDL) cholesterol, a known factor in heart disease. Despite the availability of statins and the approval of PCSK9-targeting medicines, there is still a need for new therapies.

Vaccine 130

Vaccine Immune Response Trials Clinical Trials 130

Drug Discovery World

JULY 27, 2023

Five of eight patients treated (62.5%) had a best response of immune-related stable disease, and three (37.5%) demonstrated immune-related progressive disease. The post Topline results support allogeneic cell vaccine in lung cancer appeared first on Drug Discovery World (DDW).

Vaccine 130

Vaccine Clinical Trials Engineering Disease 130

Drug Discovery World

SEPTEMBER 18, 2023

Available biomarker results for some patients show vaccine-specific T cell expansion and complete clearance or considerable drop of ctDNA, indicating activity of the treatment after just 21 days. These data were presented at the IASLC 2023 World Conference on Lung Cancer (WCLC).

Vaccine 130

Vaccine Trials Therapies Treatment 130

Drug Discovery World

JUNE 6, 2024

With the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting , taking place from 30 May to 3 June, the drug discovery announcements have been coming thick and fast, with many new cancer therapies making significant strides forward in our ability to treat the disease.

Drug Research 195

Drug Research Research Vaccine Clinical Trials 195

Drug Discovery World

DECEMBER 4, 2023

A novel DNA vaccine in combination with chemotherapy has demonstrated promising clinical results against a deadly form of ovarian cancer. The investigational compound Elenagen is an experimental DNA therapy that consists of a circular piece of DNA called a plasmid that includes a gene for a human protein called p62/SQSTM1.

DNA 147

DNA Therapies Packaging Vaccine 147

Drug Discovery World

MAY 17, 2024

From a weight loss drug that prevents heart attacks and a gene therapy that restores hearing, to a vaccine that can treat viruses that don’t exist yet, our chosen news stories this week all represent potential breakthroughs in their respective fields.

Therapies 130

Therapies Vaccine RNA Clinical Trials 130

Drug Discovery World

NOVEMBER 15, 2022

An experimental therapeutic cancer vaccine induced immune system responses that led to significant tumour regression in mice, according to investigators from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. .

Vaccine 130

Vaccine Immune Response Virus Disease 130

Drug Discovery World

APRIL 16, 2023

Personalised mRNA-based cancer vaccine mRNA-4157/V940, in combination with the immune checkpoint inhibitor pembrolizumab (Keytruda) improved recurrence-free survival (RFS) compared with pembrolizumab alone in patients with high-risk melanoma. According to the results of the primary trial analysis, after 18 months, the RFS was 78.6%

Vaccine 130

Vaccine Immune Response Medical Schools Trials 130

Drug Discovery World

MARCH 25, 2024

It looks at where we are in the fight against antimicrobial resistance, explores how structural biology is informing vaccine design, and offers advice on approaching dealmaking in biopharma. A spotlight on the future potential of mRNA-based therapies. Read the digital version here.

Therapies 162

Therapies Vaccine Disease Marketing 162

Drug Discovery World

NOVEMBER 8, 2022

Merck has exercised its option to jointly develop and commercialise personalised cancer vaccine (PCV) mRNA-4157/V940 pursuant to the terms of its existing collaboration and license agreement with Moderna. . The post Merck and Moderna to jointly develop personalised cancer vaccine appeared first on Drug Discovery World (DDW).

Vaccine 130

Vaccine Immune Response Research Laboratories Clinical Trials 130

Drug Discovery World

SEPTEMBER 6, 2022

DDW Editor Reece Armstrong looks at the cell and gene therapy landscape, examining the challenges facing developers and the trends we can expect to see throughout the year. . There’s no doubt that cell and gene therapies present some of the most exciting opportunities for emerging drugs. billion, compared to $19.9 Cancer is king .

Therapies 130

Therapies Clinical Trials Vaccine Disease 130

Drug Discovery World

FEBRUARY 10, 2023

Breast cancer retained its position as the most-studied disease area in clinical trials in 2022, despite a drop in activity, according to analysis from analytics company Phesi. The post Breast cancer still top disease area for clinical studies appeared first on Drug Discovery World (DDW). Download the full report.

Disease 130

Disease Clinical Trials Clinical Development Trials 130

FDA Law Blog: Drug Discovery

JUNE 12, 2024

Sasinowski — Hyman, Phelps & McNamara (HPM) would like to congratulate the 7 rare disease programs selected for the inaugural class of the FDA’s “Support for clinical Trials Advancing Rare disease Treatment” (START) pilot program.

Disease 59

Disease Clinical Trials FDA Clinical Development 59

Drug Discovery World

AUGUST 16, 2023

The whole world realised the power of RNA when the Covid-19 pandemic brought us the first mRNA-based vaccines. Therefore, it is now more critical than ever to advance the science to develop the next generation of RNA therapies, leveraging this molecule as a therapeutic modality with transformational potential.

RNA 130

RNA DNA Therapies Small Molecule 130

Drug Discovery World

APRIL 19, 2024

Human infection model drives forward TB vaccine development For the first time, a controlled human infection model for tuberculosis (TB) has been developed and could help with the future development of TB vaccines. The post This week in drug discovery (15-19 April) appeared first on Drug Discovery World (DDW).

Clinical Trials 130

Clinical Trials Vaccine Trials Drugs 130

Drug Discovery World

NOVEMBER 20, 2023

Engineering biology is reshaping the world, from enabling the rapid development of vaccines to providing alternatives to petroleum fuels. Biologics represents the fastest-growing sector of the pharmaceutical industry, with hundreds of therapies approved in recent years 3,4.

DNA 173

DNA Engineering Vaccine Therapies 173

Drug Discovery World

JANUARY 11, 2024

They are called: mRNA technology may hold the future for a cytomegalovirus vaccine ; Predictive diagnostics: closing the precision medicine gap ; and FAIR Game: making data work harder in the race to market. In the first article, Allison August, M.D.,

Vaccine 147

Vaccine Clinical Development Drugs Disease 147

Drug Discovery World

JANUARY 12, 2024

Perhaps most importantly, a new antibiotic was found that targets a Gram-negative pathogen, mRNA was used as an effective therapy for a rare liver disease, and a common immune cell was found to attack cancer. The post This week in drug discovery (8-12 January) appeared first on Drug Discovery World (DDW).

Immune Response 130

Immune Response Vaccine RNA Drugs 130

Drug Discovery World

OCTOBER 27, 2023

My news highlights this week feature a variety of treatment approaches, from cell therapy and antibody-drug conjugate to autotaxin inhibitor and arenaviral vaccine, all entering early in-human clinical trials to treat a range of diseases.

Vaccine 130

Vaccine Drugs Therapies Clinical Trials 130

Drug Target Review

FEBRUARY 21, 2024

Stem cell transplants have saved patients’ lives time and time again, which led us to launch our own Stem Cell Transplant and Cellular Therapy Program. Regarding CAR-T cell therapy, could you highlight the promising findings that have been identified in the early stages of drug discovery, as well as potential challenges?

Therapies 63

Therapies Treatment FDA Approval Vaccine 63

Drug Target Review

MAY 22, 2024

How does Circio’s circVec technology aim to enhance the potency and reduce the cost of current gold-standard gene therapy? As a first step, Circio is working on designing and validating circVec-AAV vectors for the treatment of genetic diseases, and testing these head-to-head against the mRNA-AAV equivalent in vivo.

Therapies 58

Therapies RNA Protein Expression DNA 58

The Pharma Data

OCTOBER 14, 2021

Biogen today announced results of a new analysis of immune response to the COVID-19 vaccine among people with multiple sclerosis (MS). Germany and Spain, researchers evaluated blood samples from 322 participants 28-90 days after their last COVID-19 vaccine dose. Using data from the MS PATHS network in the U.S.,

Vaccine 52

Vaccine Therapies Immune Response Disease 52

Vial

DECEMBER 11, 2023

Pathophysiological evidence links HCV infections to the risk of liver diseases such as hepatocellular carcinoma (HCC) and liver cirrhosis. Patients at advanced stages of liver disease can still be treated. To what extent does viral eradication reduce the risk of liver disease progression in the long term?

Clinical Research 52

Clinical Research Therapies Research Vaccine 52

Drug Discovery World

SEPTEMBER 14, 2023

Total revenue from oncology medicines increased 22%, CVRM 20%, R&I8 10%, and rare disease 12%. Vaccines were up 9.1% Moreover, in July 2023, AstraZeneca and Vaxess Technologies commenced a collaboration for the evaluation of a novel RNA-based pandemic influenza prototype vaccine in patch format. Specialty care grew 11.8%

Vaccine 147

Vaccine FDA Approval Drugs Licensing 147

Drug Discovery World

OCTOBER 30, 2023

The news highlights this week feature a variety of treatment approaches, from cell therapy and antibody-drug conjugate to autotaxin inhibitor and arenaviral vaccine, all entering early in-human clinical trials to treat a range of diseases.

Clinical Trials 130

Clinical Trials Vaccine Therapies Trials 130

Drug Discovery World

MAY 21, 2024

From a weight loss drug that prevents heart attacks and a gene therapy that restores hearing, to a vaccine that can treat viruses that don’t exist yet, our chosen news stories this week all represent potential breakthroughs in their respective fields.

Virus 147

Virus Vaccine Therapies Drugs 147

Drug Discovery World

MAY 23, 2024

A team of scientists in the US and the UK are combining a genetically modified cold sore virus with a cancer vaccine to treat an aggressive type of brain cancer in children. Researchers now want to combine the virus with a cancer vaccine called SNAPvax. million of funding for this research project.

Virus 147

Virus Immune Response Vaccine Engineering 147

Drug Discovery World

FEBRUARY 15, 2024

The etherna paradigm for cLNP design is ushering in the rapid generation of novel families of delivery systems for not only vaccination but also for in vivo tolerisation for a host of autoimmune diseases.” The post LNP formulations produce strong immune responses, data shows appeared first on Drug Discovery World (DDW).

Immune Response 130

Immune Response Vaccine RNA Pharmaceutical Companies 130

The Pharma Data

APRIL 26, 2022

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and Pfizer Inc. Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, and Pfizer Inc. NYSE: PFE) today reported positive Phase 2 pediatric data for their Lyme disease vaccine candidate, VLA15.

Vaccine 52

Vaccine Disease Protein Expression Trials 52

Drug Discovery Today

JULY 26, 2020

New state-of-the-art centre to scale up COVID-19 vaccine and gene therapy manufacturing gets £100m investment Additional £4.7m

Vaccine 113

Vaccine Therapies Disease 113

Drug Discovery World

NOVEMBER 4, 2022

In a week that saw magic mushrooms making the headlines in the UK, we also reported on exciting potential new therapies for geographic atrophy and malaria prevention. Covid-19 vaccine less effective in the immunocompromised . Covid-19 vaccine less effective in the immunocompromised . The top stories: .

Vaccine 130

Vaccine Therapies Drugs Virus 130

Drug Discovery World

JULY 10, 2023

If there’s one thing I would take from the Summer 2023 issue of Drug Discovery World , it would be that the application of technologies and processes throughout the pharmaceutical industry are changing how scientists pursue the development of therapies. Some of these will no doubt see more success than others.

Pharmaceuticals 130

Pharmaceuticals Therapies Vaccine Clinical Trials 130

Drug Discovery World

JANUARY 9, 2023

It is hoped that a new partnership between the UK government and BioNTech will help accelerate clinical trials of personalised immunotherapies for cancer and infectious disease vaccines. . The agreement means cancer patients will get early access to trials exploring personalised mRNA therapies, like cancer vaccines. .

Research 130

Research Vaccine Government Clinical Trials 130

Drug Discovery World

JANUARY 11, 2024

They are called: mRNA technology may hold the future for a cytomegalovirus vaccine ; Predictive diagnostics: closing the precision medicine gap ; and FAIR Game: making data work harder in the race to market. In the first article, Allison August, M.D.,

Vaccine 130

Vaccine Drugs Clinical Development Marketing 130

The Pharma Data

JULY 21, 2021

Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, and Pfizer Inc. at Month 7). Juan Carlos Jaramillo M.D., About VLA15.

Vaccine 52

Vaccine Disease Trials Protein Expression 52

Drug Discovery World

JULY 22, 2022

Covid-19 vaccines remain effective six months after second dose . Two doses of Covid-19 vaccines were sufficient in providing protection against severe cases of the infectious disease, according to new research.? . New combination therapy shows promise against lung cancers? .

DNA 130

DNA Clinical Trials Vaccine Virus 130